Olivier Wurtz

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/8439504/publications.pdf

Version: 2024-02-01

		933447	1125743	
15	1,856	10	13	
papers	citations	h-index	g-index	
15	15	15	2496	
15	13	15	2486	
all docs	docs citations	times ranked	citing authors	

#	Article	IF	CITATIONS
1	Chemotactic G protein-coupled receptors control cell migration by repressing autophagosome biogenesis. Autophagy, 2016, 12, 2344-2362.	9.1	25
2	The Neuropeptide PACAP, a Potent Disease Modifier Candidate for Brain Stroke Treatment. Current Topics in Neurotoxicity, 2016, , 583-606.	0.4	4
3	P2RX7 Purinoceptor: A Therapeutic Target for Ameliorating the Symptoms of Duchenne Muscular Dystrophy. PLoS Medicine, 2015, 12, e1001888.	8.4	51
4	Pituitary Adenylate Cyclase-Activating Polypeptide Reverses Ammonium Metavanadate-Induced Airway Hyperresponsiveness in Rats. Oxidative Medicine and Cellular Longevity, 2015, 2015, 1-15.	4.0	11
5	Pituitary Adenylate Cyclase Activating Peptide (1-38) and its analog (Acetyl-[Ala15, Ala20] PACAP) Tj ETQq1 1 0.7 Pharmaceutical Sciences, 2015, 51, 681-688.	784314 rg 1.2	BT /Overlock O
6	Delayed Pituitary Adenylate Cyclase–Activating Polypeptide Delivery After Brain Stroke Improves Functional Recovery by Inducing M2 Microglia/Macrophage Polarization. Stroke, 2015, 46, 520-528.	2.0	84
7	Induction of serpinb1a by <scp>PACAP</scp> or <scp>NGF</scp> is required for <scp>PC</scp> 12 cells survival after serum withdrawal. Journal of Neurochemistry, 2014, 131, 21-32.	3.9	15
8	PACAP., 2013,, 889-897.		1
9	Strategies to Convert PACAP from a Hypophysiotropic Neurohormone Into a Neuroprotective Drug. Current Pharmaceutical Design, 2011, 17, 1002-1024.	1.9	36
10	Pituitary Adenylate Cyclase-Activating Polypeptide and Its Receptors: 20 Years after the Discovery. Pharmacological Reviews, 2009, 61, 283-357.	16.0	948
11	Neurotrophic effects of PACAP in the cerebellar cortex. Peptides, 2007, 28, 1746-1752.	2.4	65
12	Dynamic molecular confinement in the plasma membrane by microdomains and the cytoskeleton meshwork. EMBO Journal, 2006, 25, 3245-3256.	7.8	443
13	IL-4-mediated inhibition of IFN-Â production by CD4+ T cells proceeds by several developmentally regulated mechanisms. International Immunology, 2004, 16, 501-508.	4.0	74
14	Repeated Antigen Exposure Is Necessary for the Differentiation, But Not the Initial Proliferation, of Naive CD4+ T Cells. Journal of Immunology, 2002, 168, 1723-1729.	0.8	93
15	A novel reporter strain to follow Cre-mediated recombination in T and NK cells. Genesis, 2002, 32, 287-292.	1.6	6